Houston innovator backed by NIH grant tackles congenital heart disease in pediatric patients

good idea

Yaxin Wang leads the IDEA Lab at the Texas Heart Institute. Photo via texasheart.org

In 1969, Dr. Denton A. Cooley implanted the first total artificial heart in a living patient. Most Houstonians know Cooley’s name, but fewer can name his colleague, Dr. Domingo Liotta, who created the device. Liotta died last year at the age of 97, but his work continues at the Texas Heart Institute.

Meet Yaxin Wang, PhD. The research engineer leads the IDEA Lab at THI. IDEA stands for Innovative Device & Engineering Applications, an apt description of what Wang and her colleagues do. She’s currently focused intensely on projects that could radically change transplantation for patients in need of an artificial heart or new, healthy lungs.

Specifically, Wang is helping to develop a pediatric left ventricular assist device (NeoVAD) to mechanically pump that part of the heart in infants and small children born with heart defects.

“There aren’t a lot of options for very small kids,” explains Wang. “That’s why we’re working on an implantable LVAD for very young kids.”

In fact, as many as 14,000 children with congenital heart disease are hospitalized each year waiting for a new heart, but only around 500 pediatric transplants actually take place.

Essentially, once patients reach their teens, their chest cavities are large enough for an adult donor heart. But smaller children means smaller rib cages and fewer available hearts. For children born with heart disease, Wang’s LVAD could be a lifesaver. Because she has crafted minimally invasive devices that were developed for long-term use, patients could live far longer than before.

The project, funded by a $2.8 million NIH grant, has a big name attached. Dr. O.H. Frazier is a THI legend who claims to have performed 900 LVAD implantations, not to mention some 1,200 heart transplants. In April, the team published their initial findings regarding the success of and improvements in making rotary LVADs over the last half-century.

A different team, also led by Frazier and Wang, received a pair of grants this summer. That includes $2.8 million from the NIH and a total of $7.8 million from a DoD focused program and a THI sub-award. Their work will center on a novel centrifugal left-ventricular assist device intended for end-stage heart failure patients, a potentially safer alternative to a heart transplant.

But Wang isn’t solely focused on the heart. Working with Dr. Gabriel Loor, a cardiothoracic surgeon at Baylor College of Medicine, Wang is also responsible for a method of preserving the lungs for a longer stretch of time, which would allow for further transport, and in the more distant future, potential genetic modification before transplantation. Using animal models for the moment, “they can survive for several hours without any issues,” says Wang.

The pioneering researcher is well on her way to making a name for herself at the Texas Heart Institute and beyond. And soon, she’ll be saving countless lives.

From Your Site Articles
The Texas Heart Institute recently received its largest charitable donation in its history. Photo courtesy of THI

Massive $32M gift from former patient, new UH deal pump big changes into Houston organization

all heart

Leadership at The Texas Heart Institute has two major things to celebrate. First, it just received a $32 million donation from a patient — the largest charitable donation in its history.

Shortly after that news came out, the institute announced a new partnership with the University of Houston Tilman J. Fertitta Family College of Medicine that allows those UH medical students to join a clinical rotation at The Texas Heart Institute. The alliance means valuable insights and experience with both inpatient and outpatient cardiology for UH's future doctors.

"Students will have the chance to develop their skills in the diagnosis and management of cardiovascular conditions and will be taught by outstanding clinical educators,” said Dr. Joseph G. Rogers, president and CEO of The Texas Heart Institute and heart failure specialist at The Texas Heart Institute Center for Cardiovascular Care, in a press release announcing the news.

A game-changing gift that's all heart

As for that mammoth gift, the $32 million donation comes from Dr. Frederick M. Weissman, a neurologist from New York who was a patient at the Institute 40 years ago. Fittingly, huis gift will be used to support cardiovascular research.

This isn't Weissman's first gift to the institution. That came following his experience there in the mid-1980s, when he was treated by world-renowned cardiac surgeon Dr. Denton A. Cooley.

In November of 1986, Weissman wrote a check for $5,000; another followed the next month, with a note that read, in part, “my conscience compels me to make another contribution to The Texas Heart Institute. I don’t think I could ever repay you for what you and your staff have done for me.” Weissman and Cooley would go on to be friends throughout their lives.

When Dr. Weissman died in 2005, he left The Texas Heart Institute $500,000. The organization recently received the residual of his estate — valued at more than $32 million.

“Those of us who were fortunate enough to work with and be trained by Dr. Cooley know he was much more than just an incredibly gifted surgeon," renowned transplant surgeon and Co-director of THI’s Center for Preclinical Surgical & Interventional Research, Dr. O.H. “Bud” Frazier, said in press materials announcing the donation. "He established lifelong relationships with his patients and encouraged all of us to do the same. Dr. Weissman’s extraordinary generosity reflects the impact Dr. Cooley still has on the Institute he founded.”

A big leap for THI and the Coogs

Looking ahead, this game-changing gift and new affiliation with UH promises big things for students, doctors, researchers, and patients.

Medical students in rotation at The Texas Heart Institute will be exposed to progressive clinical care, allowing them to gain a deep understanding of the etiology, pathophysiology and management of cardiovascular disease from prevention to the most contemporary treatments available today. This level of hands-on experience is invaluable for future physicians, and will certainly contribute to the advancement of cardiovascular medicine.

"We are honored to launch this new affiliation with Fertitta Family College of Medicine,” said Dr. Jorge Escobar, director of undergraduate medical education at The Texas Heart Institute. "With new advances in diagnostic imaging, bedside testing, and clinical trials coupled with the complex care we provide to our patients, the rotation will be an impactful experience for the students."

Pumping with growth

Meanwhile, THI recently established The Texas Heart Institute Research Innovation Fund to propel the next generation of cardiovascular research by sparking discovery, supporting innovation, and recognizing excellence in high-risk, high-reward scientific exploration.

To that end, $5 million of the Weissman bequest has been designated to match philanthropic commitments of $10,000 or greater made to THI’s Research Innovation Fund and its priority initiatives in 2023, allowing donors the opportunity to double the impact of their research investment.

Founded in 1962, THI performed the first successful heart transplant and total artificial heart implant in the United States. It has gone on to become one of the world's leading institutions for cardiovascular treatment and research.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston rises in 2026 ranking of best U.S. cities to start a business

Best for Biz

Houston has reaffirmed its commitment to a business-friendly environment and now ranks as the 26th best large U.S. city for starting a business in 2026. The city jumped up eight places after ranking 34th last year.

WalletHub's annual report compared 100 U.S. cities based on 19 relevant metrics across three key dimensions: business environment, access to resources, and costs. Factors that were analyzed include five-year business survival rates, job growth comparisons from 2020 and 2024, population growth of working-age individuals aged 16-64, office space affordability, and more.

Florida cities locked out the top five best places in America for starting a new business: Tampa, Orlando, Jacksonville, Hialeah, and St. Petersburg.

Houston's business environment ranked as the 19th best in the country, and the city ranked 51st in the "business costs" category. However, the city lagged behind in the "access to resources" ranking, coming in at No. 72 overall. This category examined metrics such as Houston's working-age population growth, the share of college-educated individuals, financing accessibility, the prevalence of investors, venture investment amounts per capita, and more.

"From the Gold Rush and the Industrial Revolution to the Internet Age, periods of innovation have shaped our economy and driven major societal progress," the report's author wrote. "However, the past few years have been particularly challenging for business owners in the U.S., due to factors such as the COVID-19 pandemic, the Great Resignation and high inflation."

Earlier this year, WalletHub declared Texas the third-best state for starting a business in 2026, and several Houston-area cities have seen robust growth after being recognized among the best career hotspots in the U.S. Entrepreneurial praise has also been extended to five local companies that were named the most innovative companies in the world, and six powerhouse female innovators that made Inc. Magazine's 2026 Female Founders 500 list.

Texas cities with strong environments for new businesses
Multiple cities in the Dallas-Fort Worth Metroplex can claim bragging rights as the best Texas locales for starting a new business. Dallas ranked highest overall — appearing 11th nationally — and Irving landed a few spots behind in the 16th spot. Arlington (No. 23), Fort Worth (No. 30), Plano, (No. 35), and Garland (No. 65) followed behind.

Only six other Texas cities earned spots in the report: Austin (No. 24), Lubbock (No. 36), Corpus Christi (No. 39), San Antonio (No. 64), El Paso (No. 67), and Laredo (No. 76).

Austin tied with Boise, Idaho and Fresno, California for the highest average growth in the number of small businesses nationally, while Corpus Christi and Laredo topped a separate list of the U.S. cities with the most accessible financing.

---

This article originally appeared on CultureMap.com.

Houston humanoid robotics startup taps Amazon veteran to lead manufacturing

new hire

Persona AI, a Houston-based startup that’s developing AI-powered humanoid robots for manufacturers and other businesses, has hired Brian Davis as head of global manufacturing.

Davis previously guided teams at Amazon Robotics and Dell Technologies. During his tenure at Amazon Robotics and Dell, both companies saw major increases in manufacturing volumes within a four-year period. Davis oversaw manufacturing, supply chain, logistics, quality assurance and real estate.

“Davis steps into this role [at Persona AI] as industrial enterprises face an urgent and accelerating challenge: a structural shortage of capacity for welding, fabrication, and heavy maintenance in dynamic environments, precisely the high-value, high-risk tasks where humanoid robots can deliver the greatest impact,” according to a company news release.

Davis comes aboard as Persona AI, founded in 2024, seeks to meet demand generated by deals with HD Hyundai and POSCO Group to make humanoids for shipyards and steel plants, and by a pilot program with the State of Louisiana.

“Now is the perfect time to accelerate our production capabilities as we rapidly close the gap between what’s possible in the lab versus what’s driving real commercial value,” Davis says.

“Building industrial-rated humanoid robots and production-deployable AI is only one piece of the puzzle,” he adds. “Producing humanoids at scale will require systematic supply chain management, stringent quality control, and building the playbook for safe, high-volume manufacturing. That’s what I’m here to build.”

Last year, Persona AI raised more than more than $10 million in pre-seed funding. The company also named a new head of commercial strategy in March.

Houston startup’s brain implant for depression advances to clinical trial

moving forward

Houston-based Motif Neurotech has received FDA approval to move forward with its first clinical trial for its innovative way to fight treatment-resistant depression and other mental health disorders.

The company has developed a brain-computer interface technology based on research from Rice University. The blueberry-sized, wirelessly powered implantable device known as the Digitally-programmable Over-brain Therapeutic (DOT) stimulator delivers electrical stimulation to brain circuits linked to depression. The DOT stimulator sits in the skull above the dura without touching the brain and is considered an alternative to transcranial magnetic stimulation, which requires multiple treatment sessions and can cause headaches.

“The goal for this technology is that it would be the mental health equivalent of a continuous glucose monitor for diabetes,” Jacob Robinson, a Rice University professor of electrical computer engineering and bioengineering and CEO of Motif Neurotech, said in a news release. “What has been really special for me personally on this journey is to be able to work all the way from a concept through the process of research and development funded by the federal government at Rice, and take that into a product that is going to affect people’s lives for the better.”

Eligible adults whose depression has not improved after trying multiple therapies can take part in the study. The clinical trial will be conducted in collaboration with Baylor College of Medicine, Brain Health Consultants (Houston), UT Health Houston, Massachusetts General Brigham, Emory Healthcare, University of Iowa, University of Utah Health and New York University, according to Rice.

Motif also announced that it was one of the first teams selected for ARPA-H’s EVIDENT initiative, which recently awarded up to $139.4 million to spur new, effective therapies for behavioral health. Through the initiative, Motif will collect additional data alongside its clinical trial.

“The idea with this funding is to support a number of teams who have rapid-acting interventions for a mental health condition and to collect additional data to help determine with greater precision whether a treatment is working, how it is working and which patients are benefitting most from which course of treatment,” Robinson added in the release.

Motif Neurotech was spun out of Robinson’s and Professor Kaiyuan Yang’s labs at Rice, along with collaborators and co-founders Dr. Sameer Sheth at Baylor College of Medicine and Dr. Sunil Sheth at the University of Texas Health Science Center at Houston. It was founded through the Rice Biotech Launch Pad. The company closed its Series A round with an oversubscribed $18.75 million last year.

View All Listings